190 related articles for article (PubMed ID: 35158776)
1. Risks of Aromatase Inhibitor-Related Cardiotoxicity in Patients with Breast Cancer in Asia.
Chang WT; Chen PW; Lin HW; Kuo YH; Lin SH; Li YH
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158776
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of adverse events of endocrine therapies among older patients with breast cancer.
Honma N; Makita M; Saji S; Mikami T; Ogata H; Horii R; Akiyama F; Iwase T; Ohno S
Support Care Cancer; 2019 Oct; 27(10):3813-3822. PubMed ID: 30729298
[TBL] [Abstract][Full Text] [Related]
3. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies.
Johnston SR
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4376s-4387s; discussion 4411s-4412s. PubMed ID: 11916228
[TBL] [Abstract][Full Text] [Related]
4. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Gibson LJ; Dawson C; Lawrence DH; Bliss JM
Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
[TBL] [Abstract][Full Text] [Related]
5. Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors.
Grouthier V; Lebrun-Vignes B; Glazer AM; Touraine P; Funck-Brentano C; Pariente A; Courtillot C; Bachelot A; Roden DM; Moslehi JJ; Salem JE
Heart; 2018 Nov; 104(22):1859-1863. PubMed ID: 29720397
[TBL] [Abstract][Full Text] [Related]
6. Vascular effects of aromatase inhibitors: data from clinical trials.
Howell A; Cuzick J
J Steroid Biochem Mol Biol; 2005 May; 95(1-5):143-9. PubMed ID: 15936188
[TBL] [Abstract][Full Text] [Related]
7. Endocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare Part D.
Riley GF; Warren JL; Harlan LC; Blackwell SA
Medicare Medicaid Res Rev; 2011 Dec; 1(4):. PubMed ID: 22340780
[TBL] [Abstract][Full Text] [Related]
8. Regular use of aspirin is associated with a lower cardiovascular risk in prostate cancer patients receiving gonadotropin-releasing hormone therapy.
Chang WT; Hong CS; Hsieh KL; Chen YC; Ho CH; Shih JY; Kan WC; Chen ZC; Lin YC
Front Oncol; 2022; 12():952370. PubMed ID: 36172150
[TBL] [Abstract][Full Text] [Related]
9. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
Howell A; Howell SJ; Clarke R; Anderson E
J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):227-37. PubMed ID: 11850229
[TBL] [Abstract][Full Text] [Related]
10. Safety profiles of aromatase inhibitors and selective estrogen-receptor modulators in the treatment of early breast cancer.
Yamamoto Y; Iwase H
Int J Clin Oncol; 2008 Oct; 13(5):384-94. PubMed ID: 18946748
[TBL] [Abstract][Full Text] [Related]
11. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Postmenopausal Breast Cancer with Selective Estrogen Receptor Modulators (SERMs).
Lewis-Wambi JS; Jordan VC
Breast Dis; 2005-2006; 24():93-105. PubMed ID: 16917142
[TBL] [Abstract][Full Text] [Related]
13. Risks of trastuzumab-related cardiotoxicity in breast cancer patients in Taiwan.
Chang WT; Chen PW; Lin HW; Lin SH; Li YH
ESC Heart Fail; 2021 Dec; 8(6):5149-5158. PubMed ID: 34480791
[TBL] [Abstract][Full Text] [Related]
14. Aromatase inhibitors in breast cancer prevention.
Olin JL; St Pierre M
Ann Pharmacother; 2014 Dec; 48(12):1605-10. PubMed ID: 25159003
[TBL] [Abstract][Full Text] [Related]
15. Aromatase inhibitors and selective estrogen receptor modulators: Unconventional therapies for functional hypogonadism?
Awouters M; Vanderschueren D; Antonio L
Andrology; 2020 Nov; 8(6):1590-1597. PubMed ID: 31696669
[TBL] [Abstract][Full Text] [Related]
16. Socio-demographic and geographic variations in the utilization of hormone therapy in older women with breast cancer after Medicare Part-D coverage.
Wang X; Du XL
Med Oncol; 2015 May; 32(5):154. PubMed ID: 25837434
[TBL] [Abstract][Full Text] [Related]
17. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Baumann CK; Castiglione-Gertsch M
Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
[TBL] [Abstract][Full Text] [Related]
18. Perioperative Use of Antiestrogen Therapies in Breast Reconstruction: A Systematic Review and Treatment Recommendations.
Spera LJ; Cook JA; Dolejs S; Fisher C; Lester ME; Hassanein AH
Ann Plast Surg; 2020 Oct; 85(4):448-455. PubMed ID: 32332390
[TBL] [Abstract][Full Text] [Related]
19. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Gibson L; Lawrence D; Dawson C; Bliss J
Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD003370. PubMed ID: 19821307
[TBL] [Abstract][Full Text] [Related]
20. Aromatase inhibitors with or without luteinizing hormone-releasing hormone agonist for metastatic male breast cancer: report of four cases and review of the literature.
Kuba S; Ishida M; Oikawa M; Nakamura Y; Yamanouchi K; Tokunaga E; Taguchi K; Esaki T; Eguchi S; Ohno S
Breast Cancer; 2016 Nov; 23(6):945-949. PubMed ID: 26879549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
